CSL-p53: From senescence to CAF activation. by Procopio, M.G. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but does not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: CSL-p53: From senescence to CAF activation. 
Authors: Procopio MG, Laszlo C, Dotto GP 
Journal: Cell cycle (Georgetown, Tex.) 
Year: 2016 
Volume: 15 
Issue: 4 
Pages: 485-6 
DOI: 10.1080/15384101.2015.1130091 
 
CSL-p53: from senescence to CAF activation 
 
Maria-Giuseppina Procopio1♯, Csaba Laszlo1♯ and G. Paolo Dotto1,2*. 
 
1 Department of Biochemistry, University of Lausanne, Epalinges, CH-1066, Switzerland; 
2 Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA 02129, USA 
♯ Equal contributors 
* Corresponding author:  G. Paolo Dotto  email: Paolo.Dotto@unil.ch 
 
 
 
 
Crosstalk between the epithelial and stromal compartment is essential to maintain tissue 
homeostasis. Normal tissue environment can suppress the ability of incipient neoplastic cells to survive 
and proliferate; as a consequence, tumor cells often acquire the ability to create a permissive 
microenvironment. So far, genetic and epigenetic changes of the epithelium have been implicated as 
likely primary determinants of carcinogenesis, while alterations of the underlying mesenchyme have been 
assumed to be only a reactive consequence of a stromal-epithelial co-evolution process. Increasing 
amount of evidence points to the ability of the microenvironment to acquire a pro-carcinogenic state 
independently of the presence of tumor cells. Alteration of the stromal microenvironment, such as the 
appearance of cancer-associated fibroblasts (CAFs), is emerging as an important event in tumor initiation 
as well as progression.1  
We previously showed that mesenchymal deletion of CSL, the key effector of “canonical” Notch 
signaling, endowed with an intrinsic repressive function, results in spontaneous multifocal keratinocyte 
tumor formation, preceded by CAF phenotype acquisition in both mouse and human stromal fibroblast.2 
Recently we discovered, in the same mouse and human cell system, that CAF activation is accompanied 
by stromal cell senescence and that the two events are genetically linked.3  
More specifically, deletion or silencing of the CSL gene in dermal fibroblasts induces cellular 
senescence and increased expression of senescence determinants, such as p15, p16, p21 and miR-34a. 
In parallel, CSL silencing also results in induction of the senescence messaging secretome (SMS) 
constituents, such as IL6, IL8, Pai-1 and MMPs. We also identified key senescence-effector genes, 
specifically p16, p21, miR-34a and IL6, together with a broad spectrum of CAF effector genes as direct 
targets of CSL transcriptional repression.  
Two CSL binding sites on p21 promoter have adjacent p53 recognition sequences, raising the 
possibility of direct interaction between the two proteins. Indeed, we subsequently uncovered that CSL 
and p53 can physically interact and that CSL suppresses p53 activity, blocking its association to p300, a 
critical chromatin modifier and transcriptional activator. 
Previous work has shown that stromal cell senescence can be associated with induction of 
SMS and CAF effector genes yet whether or not the two events can be genetically dissociated remained 
unclear.4 We therefore set out to test the impact of p53, a well-known determinant of cellular 
senescence, on CSL dependent senescence and CAF activation. We found that loss of p53 overcame 
the senescence driven by CSL knockdown. Surprisingly, concomitant CSL and p53 silencing also 
enhanced the expression of CAF effector genes, like Cox-2 and periostin, known to be involved in 
inflammation and macrophage recruitment.  To assess the in vivo significance of these findings, we 
developed a mouse ear intradermal injection assay for cancer and stromal cell expansion by in vivo 
imaging of fluorescently labeled cells. Skin or head & neck squamous cell carcinoma (SCC) cells 
admixed with fibroblasts deficient for both CSL and p53 showed enhanced outgrowth, 
leukocyte/macrophage infiltration and angiogenesis in comparison with CSL alone. 
In most cases, in situ epithelial lesions do not progress into an invasive cancer and additional 
genetic changes are needed for progression into a malignancy. The events governing this process are 
not fully understood, but most likely a tumor-permissive microenvironment is required.5 Stromal changes 
associated with cell senescence are thought to play an important role in the increased incidence of age-
related cancers.6 However, this process may be more relevant in the initial phase of cancer 
development rather than at advanced stage, the latter being characterized by increased fibroblast 
density and proliferation.7 Concurring with this possibility, we found senescent stromal cells in human 
premalignant skin lesions, actinic keratosis (AK) and in situ SCC, while little or none could be detected 
in invasive SCCs. Stromal dermal fibroblasts underlying AK, in situ and invasive SCC showed CSL 
down-modulation, while p53 gene expression was down-modulated only in SCCs. Furthermore, relative 
to normal HDFs, SCC-derived CAFs showed lower levels of CSL. Importantly, CSL over-expression in 
these cells resulted in suppression of CAF markers and their ability to promote SCC cell proliferation in 
vivo. The SCC-derived CAFs were also found to have lower p53 levels compared to normal HDFs, with 
FGF-2 paracrine signaling as the probable culprit of p53 down-modulation. 
Thus far two apparently conflicting cellular events were linked to CAF determination. On one 
hand, fibroblast senescence was implicated as an important factor in CAF phenotype acquisition, with 
the SMS secretome leading to inflammation and tumorigenesis. On the other hand, hyperproliferating 
CAFs causing tumor-associated fibrosis were observed surrounding malignant epithelial tumors.  
Our findings reconcile the two biological events and point to a multistep process of CAF 
activation under convergent CSL and p53 control. Activation of p53 provides a failsafe mechanism 
against consequences of compromised CSL activity in stromal cells. Concomitant p53 and CSL down-
regulation are involved in subsequent stromal and cancer cell expansion (Fig. 1). 
 
  
                 
 
Figure 1.  Combined CSL-p53 control of multistep CAF determination regulates tumor evolution.  
Left: CSL acts as a constitutive direct repressor of multiple senescence- and CAF-effector genes; it also 
physically interacts with p53 and represses its activity. Concomitant p53 and CSL loss in HDFs blocks 
senescence and enhances CAF effector gene expression. 
Right: Firstly, environmental insults like UVA irradiation and smoke can cause CSL down-modulation 
and stromal cell senescence. Secondly, paracrine influence of incipient cancer cells, like FGF-2 
secretion, is involved in p53 suppression leading to stromal and tumor cell expansion.  
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